ClinicalTrials.gov
public full text
Public Domain
Study Evaluating the Safety and Tolerability of NSA-789
This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia#1047055
- 52-week Open Label Safety-Tolerability Study#830078
- Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia#1153789
- MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects#1085732
- S228. TOWARD EARLY DETECTION OF TREATMENT RESISTANT SCHIZOPHRENIA: PREDICTIVE INFORMATION ON NON-RESPONSE TO ANTIPSYCHOTICS BY EVALUATION OF A FEW CLINICAL FACTORS: A STUDY BY ROC CURVE ANALYSIS AND CONFIRMATORY MULTIVARIATE ANALYSIS#685228
Record · ID 862851
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive